Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› UK
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in the UK: Industry-Sponsored Studies

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2868 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 15 Oct 2026, 03:15 UTC
2868
Studies in scope
industry-sponsored, all four open statuses
1384
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2021 Manchester 667 Birmingham 482 Glasgow 437 Cambridge 424
Narrow the register
Recruitment status
Phase
Lead sponsor
AstraZeneca195 Merck Sharp & Dohme LLC114 Hoffmann-La Roche106 Novartis Pharmaceuticals98 Janssen Research & Development, LLC92
Site city
London2021 Manchester667 Birmingham482 Glasgow437 Cambridge424
All 430 cities
Target enrolment
to

Trials in this register

2868 of 2868 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Not yet open
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
Birmingham, London, Glasgow, Cardiff, Manchester
2027-11-23
Not yet open
First In Human Randomised Trial of Rincell-1 in Adults With a Cochlear Implant
NCT07032038Sensorineural Hearing Loss, Presbyacusis, Auditory Neuropathy
Rinri Therapeutics
Phase 1/2
20
Birmingham, Cambridge, London
2027-09
Not yet open
Transdermal Delivery Solutions Corp
Phase 2
48
London
2027-06
Not yet open
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
92
London, Leeds, Sheffield
2027-02-03
Not yet open
OneCarbon
Not applicable
20
Cambridge
2027-01-01
Not yet open
Adagio Medical
Not applicable
130
Basildon
2027-01-01
Not yet open
Novonesis
Not applicable
300
Cardiff
2027-01
Not yet open
Bristol-Myers Squibb
Phase 3
2,380
Birmingham, Cambridge, Edinburgh, London, Peterborough, Cottingham, Leeds, Oxford
2026-12-16
Not yet open
iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma
NCT07815574Melanoma (Skin Cancer), Advanced Melanoma, Metastatic Melanoma, Skin Cancer
DrugsImmunoBody·Yervoy·Ipilimumab·Opdivo
Scancell Ltd
Phase 3
550
London
2026-12-01
Not yet open
AbbVie
Phase 3
520
Plymouth, Edinburgh, London, Portsmouth, Airdrie, Nottingham
2026-11-30
Recruiting
Hoffmann-La Roche
Phase 3
1,600
Aberdeen, Birmingham, Chertsey, Edinburgh, London, Southampton
2026-11-30
Not yet open
Bristol-Myers Squibb
Phase 2
80
Leicester, Metropolitan Borough of Wirral, London
2026-11-30
Not yet open
Microbio Co Ltd
Observational
1,500
Bristol
2026-11
Not yet open
Chiesi Farmaceutici S.p.A.
Phase 1
24
Leeds
2026-10-27
Not yet open
Novo Nordisk A/S
Phase 3
8,500
Newquay, Poole, Thetford, West Bromwich, Chichester, West Kirby, Aberdeen, Ashton-under-Lyne
2026-10-26
Not yet open
Boehringer Ingelheim
Phase 3
600
Leicester
2026-10-23
Not yet open
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT07707895Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology, Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology
DrugsZL-1310·Obrixtamig·Atezolizumab
Boehringer Ingelheim
Phase 1/2
60
Leicester, Newcastle upon Tyne
2026-10-19
Not yet open
Market Research of a Slow Release Protein Substitute for the Dietary Management of PKU
NCT07802366Phenylketonuria (PKU) and Hyperphenylalaninemia, Brain Diseases, Metabolic, Inborn, Brain Disorder, Metabolic, Brain Diseases
metaX Institut fuer Diatetik GmbH
Not applicable
10
Birmingham
2026-10-15
Not yet open
Medtronic MiniMed, Inc.
Not applicable
230
Cambridge, Leicester, Manchester
2026-10-15
Not yet open
Chiesi Farmaceutici S.p.A.
Phase 1
18
Leeds
2026-10-14
Not yet open
Novo Nordisk A/S
Phase 3
84
Birmingham, Cardiff, London, Oxford, Sheffield
2026-10-09
Recruiting
Chiesi Farmaceutici S.p.A.
Phase 1
120
Leeds, London, Manchester
2026-10-02
Not yet open
PKU Microtablets Case Studies
NCT07671859Phenylketonuria (PKU)
Nutricia UK Ltd
Not applicable
20
Bristol
2026-10-01
Not yet open
Zoll Medical Corporation
Not applicable
800
Southampton
2026-10-01
Not yet open
Europa Life Sciences Limited
Not applicable
6
Royal Tunbridge Wells
2026-10-01
Recruiting
Yaqrit Ltd
Not applicable
72
London
2026-10
Not yet open
Tangram Therapeutics Plc
Phase 1
40
London
2026-10
Not yet open
Assembly Biosciences
Phase 2
80
London, Manchester
2026-10
Recruiting
A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.
NCT07559175Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF), Pancreatic Enzyme Abnormality, Pancreatic Diseases
DrugZenpep
Aimmune Nestlé Health Science US R&D, LLC
Phase 2
66
Liverpool, Belfast, Glasgow, Newcastle upon Tyne
2026-10
Not yet open
Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer
NCT07808151Colon Cancer, Microsatellite Stable (MSS) Colon Cancer, Proficient Mismatch Repair (pMMR) Colon Cancer
DrugsPorustobart·Keytruda·Pembrolizumab
Solstice Oncology, Inc.
Phase 2
100
Aberdeen, Cardiff, Glasgow, Leeds, London
2026-09-30
Recruiting
Zedsen Limited
Observational
220
London
2026-09-30
Recruiting
Corbus Pharmaceuticals Inc.
Phase 3
260
London, Sutton, Birmingham, Cambridge, Glasgow, Liverpool, Manchester, Nottingham
2026-09-29
Recruiting
Charm Therapeutics
Phase 1
40
Oxford
2026-09-28
Recruiting
HALEON
Not applicable
20
Birmingham
2026-09-28
Recruiting
Joey Porter
Not applicable
24
Bracknell
2026-09-22
Recruiting
Amgen
Phase 1
308
Leeds
2026-09-22
Recruiting
Boehringer Ingelheim
Phase 3
466
Birmingham, Exeter, Lancaster, Leeds, Leicester, London, Manchester, Oxford
2026-09-17
Recruiting
Sanofi
Phase 3
1,508
Rotherham
2026-09-16
Recruiting
Weight and Metabolic Management Study
NCT07789223Overweight, Obesity, Weight Maintenance
Elenzia
Not applicable
200
Redditch
2026-09-15
Recruiting
CSL Behring
Phase 3
63
London, Leicester
2026-09-15
Recruiting
Vividion Therapeutics, Inc.
Phase 2
140
London, Coventry
2026-09-11
Recruiting
A Study in Adults With Geographic Atrophy
NCT07606365Geographic Atrophy
DrugSTL303
Sitala Bio LTD
Phase 2
300
London, Southampton, Leicester, Newcastle upon Tyne
2026-09-11
Recruiting
Takeda
Phase 3
324
Lincoln, Leicester, London, Sunderland, Birmingham
2026-09-10
Recruiting
Bristol-Myers Squibb
Phase 2
160
Birmingham, London, Guildford
2026-09-10
Recruiting
Sanofi
Phase 2
8,000
Cardiff, Bournemouth, Dorchester, London, Portsmouth, Blackpool, Witney, West Kirby
2026-09-09
Recruiting
JCR Pharmaceuticals Co., Ltd.
Phase 1/2
12
London
2026-09-09
Recruiting
Janssen Research & Development, LLC
Phase 3
1,000
Blackpool, Cambridge, Canterbury
2026-09-09
Recruiting
Agomab Spain S.L.U.
Phase 1
8
Nottingham
2026-09-09
Recruiting
RyCarma Therapeutics, Inc.
Phase 2
28
Oswestry, London
2026-09-09
Recruiting
Incyte Corporation
Phase 3
426
Cambridge, Edinburgh, Harrow, Leeds, London, Newcastle upon Tyne, Oxford, Penzance
2026-09-08
Recruiting
Novartis Pharmaceuticals
Phase 1
30
Nottingham
2026-09-02
Recruiting
AusperBio Therapeutics Inc.
Phase 2
70
London
2026-09-01
Recruiting
AstraZeneca
Phase 3
2,800
Aberdeen, Bristol, Cardiff, Dundee, Glasgow, London, Swansea
2026-09-01
Not yet open
The Efficacy and Safety Study of 2107 Injection in Subjects With Mild to Moderate Knee Osteoarthritis
NCT07746843Mild Knee Osteoarthritis, Moderate Knee Osteoarthritis
BioRegen Biomedical (Changzhou) Co., Ltd
Not applicable
286
Glasgow
2026-09-01
Recruiting
GlaxoSmithKline
Phase 3
110
Great Cambourne, Greater Manchester
2026-09-01
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping
NCT07587242Muscular Dystrophies, Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy), Muscular Disorders, Atrophic, Muscular Disease
DrugAOC 1044
Avidity Biosciences, Inc.
Phase 3
70
Newcastle, Oxford
2026-09-01
Recruiting
Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired Subpopulations
NCT07654855Transthyretin Amyloidosis, Transthyretin Amyloidosis With Cardiomyopathy, Transthyretin Amyloidosis With Polyneuropathy
AstraZeneca
Observational
320
Birmingham
2026-09-01
Not yet open
Eli Lilly and Company
Phase 3
170
Hull, Liverpool, London
2026-09
Not yet open
AeroRx Therapeutics Inc.
Phase 1
24
Manchester
2026-09
Not yet open
Essilor International
Not applicable
96
London
2026-09
Not yet open
CooperVision International Limited (CVIL)
Not applicable
58
Birmingham
2026-09
Not yet open
Novonesis
Not applicable
150
Cardiff
2026-09
Recruiting
Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT07665515Ovarian Cancer, HGSOC, HGS Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Epitopea Ltd
Phase 1
50
Cambridge, Edinburgh, Glasgow, Leeds, Leicester, London, Preston, Sutton
2026-09
Not yet open
HALEON
Not applicable
192
Bristol
2026-09
Recruiting
Salts Healthcare
Observational
108
Birmingham
2026-09
Recruiting
Ascletis Pharma (China) Co., Limited
Phase 3
3,003
Bellshill, Cardiff, Edgbaston, London, Manchester, Stoke-on-Trent, Warrington
2026-08-31
Not yet open
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
52
London, Sheffield
2026-08-31
Recruiting
AstraZeneca
Phase 3
1,072
Cambridge, Leeds, London, Newcastle upon Tyne, Sheffield
2026-08-31
Not yet open
Eisai Limited
Observational
400
Edinburgh, London, Motherwell
2026-08-31
Recruiting
Intuitive Surgical
Phase 4
550
London
2026-08-28
Recruiting
Ascletis Pharma (China) Co., Limited
Phase 3
1,560
Cardiff, Edgbaston, Glasgow, London, Manchester, Stoke-on-Trent, Warrington
2026-08-28
Recruiting
Kardigan, Inc.
Phase 3
332
Bristol, Glasgow, Leicester, London, Oxford
2026-08-26
Not yet open
AstraZeneca
Phase 3
750
Cambridge, London
2026-08-25
Recruiting
Novo Nordisk A/S
Phase 3
1,778
Newquay, Yeovil, Rotherham, Bristol, Coventry, Hull, Ipswich, Londonderry
2026-08-24
Recruiting
AstraZeneca
Phase 3
500
Airdrie, Chippenham, Hull, Llandough, Rotherham
2026-08-24
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Ashton-under-Lyne, Basildon, Belfast, Birmingham, Brighton, Bristol, Cardiff, Clydebank
2026-08-24
Recruiting
AstraZeneca
Phase 3
7,000
Aberdeen, Cardiff, Corby, Coventry, Dundee, Glasgow, Leicester, Liverpool
2026-08-21
Recruiting
AstraZeneca
Phase 3
1,500
Chippenham, Corby, Dunfermline, Hull, Northwood
2026-08-20
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
472
Cambridge
2026-08-20
Recruiting
Trace Neuroscience, Inc.
Phase 1/2
30
London, Sheffield
2026-08-20
Recruiting
CRISM Therapeutics LTD
Phase 2
147
Birmingham
2026-08-20
Recruiting
35Pharma Inc
Phase 1/2
90
London
2026-08-19
Recruiting
GlaxoSmithKline
Phase 1
24
Cambridge
2026-08-18
Recruiting
Hoffmann-La Roche
Phase 3
100
London, Sheffield
2026-08-18
Recruiting
VarmX B.V.
Phase 3
800
Gloucester, London, Birmingham, Edinburgh
2026-08-18
Recruiting
Pivotal Study of N-acetyl-L-leucine for CACNA1A
NCT07221292CACNA1A, Spinocerebellar Ataxia Type 6, Episodic Ataxia Type 2, Familial Hemiplegic Migraine-1
DrugN-Acetyl-L-Leucine
IntraBio Inc
Phase 3
60
Newcastle upon Tyne, Oxford
2026-08-17
Recruiting
Eli Lilly and Company
Phase 3
1,000
Bodmin, Edinburgh, Exeter, Glasgow, Liverpool, Motherwell, Oxford, Penzance
2026-08-14
Recruiting
Takeda
Phase 2
20
Oxford
2026-08-13
Recruiting
Genespire Srl
Observational
30
London, Manchester
2026-08-13
Recruiting
AstraZeneca
Phase 3
600
Coventry, Knutsford, London, Orpington, Poole, Shipley
2026-08-12
Recruiting
ModernaTX, Inc.
Phase 1
375
Manchester, Southampton, Norwich, Birmingham, London, Newcastle
2026-08-11
Recruiting
Denali Therapeutics Inc.
Phase 1
178
Manchester
2026-08-07
Recruiting
Eli Lilly and Company
Phase 2
606
Cheadle, Ely, Hounslow, London, Penzance, West Kirby
2026-08-07
Recruiting
Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study
NCT07746895C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
DrugPegcetacoplan
Swedish Orphan Biovitrum
Phase 4
150
Cambridge, Cardiff, Glasgow, Leicester, London, Manchester, Newcastle, Salford
2026-08-05
Recruiting
Vifor Fresenius Medical Care Renal Pharma
Phase 2
18
Glasgow, Liverpool
2026-08-04
Recruiting
AbbVie
Observational
100
Plymouth
2026-08-03
Not yet open
EBI Anti Sepsis BV
Phase 3
300
London
2026-08-01
Recruiting
VectivBio AG
Phase 3
124
London, Aberdeen, Birmingham, Salford
2026-08
Not yet open
Entrada Therapeutics, Inc.
Phase 2
80
Leeds, Liverpool, London, Manchester, Newcastle upon Tyne, Oxford
2026-08
Recruiting
AstraZeneca
Phase 1
32
Harrow
2026-07-30
Recruiting
HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB
NCT07575308Von Willebrand Disease (VWD), Heavy Menstrual Bleeding (HMB)
DrugALN-6400
Alnylam Pharmaceuticals
Phase 2
24
Bradford, Oxford, Truro
2026-07-30
Recruiting
Amgen
Phase 3
950
Birmingham
2026-07-29
Recruiting
Boehringer Ingelheim
Phase 3
448
Bristol, Leeds, London, Salford
2026-07-27
Recruiting
GlaxoSmithKline
Phase 1
40
Manchester
2026-07-27
Recruiting
GlaxoSmithKline
Phase 3
800
London, Sheffield
2026-07-27
Recruiting
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
NCT07444567Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)
DrugsFasenra·Benralizumab
AstraZeneca
Phase 3
230
London
2026-07-24
Recruiting
Cochlear
Not applicable
20
London, Nottingham, Sheffield
2026-07-24
Recruiting
AstraZeneca
Phase 1
160
Harrow
2026-07-23
Recruiting
Boehringer Ingelheim
Phase 3
35
Birmingham, London
2026-07-21
Recruiting
Embody Orthopaedic Limited
Not applicable
200
Bournemouth, Coventry, Truro
2026-07-21
Recruiting
Amgen
Phase 2
15
Oxford
2026-07-21
Recruiting
AstraZeneca
Phase 3
915
Bristol, Cambridge, Preston, Sheffield
2026-07-16
Recruiting
Sensory Cloud, Inc.
Phase 2
60
Belfast, London
2026-07-13
Recruiting
Carl Zeiss Meditec AG
Phase 4
130
Ayr
2026-07-13
Recruiting
Boehringer Ingelheim
Phase 3
390
Cambridge, Edinburgh, Manchester
2026-07-10
Recruiting
LARKSPUR BIOSCIENCES, INC.
Phase 1/2
120
Edinburgh
2026-07-07
Recruiting
AstraZeneca
Phase 3
2,000
Blackburn, Dundee, Guisborough, Nantwich, Rotherham, Thetford, Weston-super-Mare, Witney
2026-07-06
Recruiting
AstraZeneca
Phase 3
900
Blackpool, Glasgow, Hull, Penzance, Sandbach, Thetford, Whitney
2026-07-06
Recruiting
AstraZeneca
Phase 3
1,200
Aberdeen, Addlestone, Banbury, Bristol, Edinburgh, Hounslow, Penzance, Poole
2026-07-06
Recruiting
Clinical Investigation of the Performance of Epinamel for Dental White Spot Lesions
NCT07730359White Spot Lesions [Initial Caries] on Smooth Surface of Tooth
Mintech Bio Ltd
Not applicable
20
London
2026-07-06
Recruiting
Axonics, Inc.
Observational
55
Sheffield
2026-07-02
Recruiting
Stealth BioTherapeutics Inc.
Phase 4
48
Bristol
2026-07-02
Not yet open
Genie Fertility Ltd
Observational
100
London
2026-07-01
Recruiting
Prilenia
Phase 3
400
Aberdeen, Birmingham, Cardiff, Liverpool, Newcastle upon Tyne
2026-07-01
Recruiting
Dompé Farmaceutici S.p.A
Phase 3
272
London, Liverpool
2026-07-01
Not yet open
GE Healthcare
Not applicable
50
London
2026-07
Recruiting
Hollister Incorporated
Not applicable
107
Stockton-on-Tees, Saint Leonards-on-Sea, Ashford, Margate, Redhill, Coventry
2026-06-30
Active, closed
Boehringer Ingelheim
Phase 2
344
Blackpool, Guisborough, High Wycombe, Leicester, Middlesbrough, Oxford
2026-06-30
Recruiting
EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety
NCT07523581Alport Syndrome, X-Linked, Alport Syndrome, Autosomal Recessive
Eloxx Pharmaceuticals, Inc.
Phase 2
24
Liverpool, London, Manchester
2026-06-30
Not yet open
Human ADME Study of [14C]-AZD1390
NCT07643870Advanced Solid Malignancies
DrugAZD1390
AstraZeneca
Phase 1
8
Guildford, Liverpool
2026-06-30
Recruiting
Hoffmann-La Roche
Phase 1
25
Liverpool, London, Newcastle upon Tyne
2026-06-29
Recruiting
AstraZeneca
Phase 3
4,500
Ashton-under-Lyne, Blackpool, Chesterfield, Corby, Ely, Glasgow, Hounslow, Leicester
2026-06-29
Recruiting
A-TANGO Phase 2 Study
NCT06890039Acute-On-Chronic Liver Failure, Alcoholic Hepatitis, Liver Cirrhosis, Alcoholic
DrugsFilgrastim·G-Csf
Yaqrit Ltd
Phase 2
78
London
2026-06-29
Recruiting
Novartis Pharmaceuticals
Phase 2
60
London
2026-06-26
Recruiting
First-in-Human, Dose Escalation Trial of AXV-101 in BBS1-Related Retinal Degeneration
NCT07269665Bardet-Biedl Syndrome 1, Retinal Degeneration
Axovia Therapeutics
Early Phase 1
12
London
2026-06-26
Recruiting
AstraZeneca
Phase 3
750
Edinburgh, London, Manchester
2026-06-26
Recruiting
Gold Standard Phantoms
Observational
66
London
2026-06-26
Recruiting
ViiV Healthcare
Phase 3
564
Birmingham, Liverpool, London
2026-06-25
Recruiting
Hoffmann-La Roche
Phase 3
380
London, Oxford, Wolverhampton
2026-06-23
Recruiting
GlaxoSmithKline
Phase 1/2
64
Manchester, London
2026-06-22
Recruiting
GlaxoSmithKline
Phase 3
450
London
2026-06-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
310
Leeds
2026-06-18
Recruiting
Post-Market Clinical Follow-up (PMCF) Study of the Pitch-Patch for the Augmentation or Reinforcement of the Rotator Cuff
NCT05906004Rotator Cuff Tear, Rotator Cuff Tears, Rotator Cuff Tears of the Shoulder, Rotator Cuff Injuries
Xiros Ltd
Observational
37
Reading
2026-06-16
Active, closed
AstraZeneca
Phase 2
326
London
2026-06-11
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Bristol, Cottingham, Edinburgh, Exeter, Liverpool, London
2026-06-11
Active, closed
Open-Label Extension Study of BBP-418 (Ribitol) for LGMD2I/R9
NCT07678775Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
DrugRibitol
ML Bio Solutions, Inc.
Phase 3
107
London, Newcastle upon Tyne
2026-06-05
Recruiting
Camurus AB
Observational
200
Leeds
2026-06-05
Recruiting
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07562152Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Immuneering Corporation
Phase 3
510
London, Manchester
2026-06-05
Recruiting
GlaxoSmithKline
Phase 3
600
Sutton, Leicester, London
2026-06-04
Recruiting
A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
NCT07359820FGFR2 Gene Fusion/Rearrangement, Other Solid Tumors, Adult
Elevar Therapeutics
Phase 2
30
London, Manchester
2026-06-04
Recruiting
AstraZeneca
Phase 1/2
152
Belfast, Fulham, Guildford, London, Newcastle upon Tyne, Oxford
2026-06-03
Recruiting
Dompé Farmaceutici S.p.A
Phase 3
150
Bristol, Liverpool, London, Nottingham
2026-06-02
Recruiting
Eli Lilly and Company
Phase 3
252
Birmingham, Bristol, Cheadle, Lancaster, Lincoln, Newcastle, Oxford, Sheffield
2026-06-01
Recruiting
Myota GmbH
Not applicable
120
London
2026-06-01
Recruiting
Bayer
Phase 3
117
Leicester, Liverpool, Belfast, Glasgow, Newcastle upon Tyne, Leeds, Bristol
2026-06-01
Not yet open
RAI Services Company
Not applicable
200
Cheshunt, Sheffield
2026-06
Not yet open
Traws Pharma, Inc.
Phase 2
165
London
2026-06
Not yet open
Artivion Inc.
Observational
110
Blackpool, Middlesbrough
2026-06
Recruiting
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
NCT07101328Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Eli Lilly and Company
Phase 1
215
Leeds, Oxford
2026-05-28
Recruiting
Pfizer
Phase 2
24
London, Bristol, Liverpool, Sheffield
2026-05-28
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 3
250
Exeter, Newcastle upon Tyne, Windsor
2026-05-25
Recruiting
Janssen Research & Development, LLC
Phase 3
644
Cambridge, Cardiff, Dundee, Leytonstone, London, Newcastle upon Tyne
2026-05-23
Recruiting
Revolution Medicines, Inc.
Phase 3
670
London
2026-05-22
Recruiting
Janssen Research & Development, LLC
Phase 3
460
Birmingham, Cardiff, Dundee, Glasgow, London, Newcastle upon Tyne
2026-05-22
Recruiting
BeOne Medicines
Phase 3
1,056
Guildford, Maidstone
2026-05-22
Recruiting
Kite, A Gilead Company
Phase 3
550
Cardiff, London, Newcastle upon Tyne
2026-05-22
Recruiting
Hoffmann-La Roche
Phase 2/3
650
Leicester, Liverpool, London, Manchester, Montacute
2026-05-21
Recruiting
Alfasigma S.p.A.
Phase 3
65
Bristol, Leicester, Nottingham
2026-05-21
Recruiting
Takeda
Phase 3
300
Leicester, Boston, Oxford, Birmingham, London, Manchester
2026-05-21
Recruiting
Regeneron Pharmaceuticals
Phase 3
270
Truro, Norwich, Leicester
2026-05-21
Recruiting
Lumos Pharma
Phase 3
150
Liverpool, London, Sheffield
2026-05-20
Recruiting
AbbVie
Phase 1
18
Cambridge
2026-05-20
Recruiting
Incyte Corporation
Phase 2
60
Birmingham, Cambridge, Glasgow, Leeds, London, Manchester, Newcastle, Sheffield
2026-05-20
Recruiting
Novartis Pharmaceuticals
Phase 1
24
London
2026-05-19
Recruiting
Takeda
Phase 2
222
Cornhill, Luton, Glasgow, London
2026-05-17
Recruiting
Hoffmann-La Roche
Phase 3
138
London, Cardiff, Oxford
2026-05-15
By invitation
Recovery and Early Sleep Tracking Using the SuperPatch REM Patch
NCT07785960Shift Work Sleep Disorder, Shift Work Type Circadian Rhythm Sleep Disorder, Shift Work Sleep Disorders
SuperPatch Limited LLC
Not applicable
20
Birmingham
2026-05-15
Recruiting
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
NCT07486934Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy, Steinert Disease
DrugZeleciment basivarsen
Dyne Therapeutics
Phase 3
150
London, Salford
2026-05-14
Recruiting
Ipsen
Phase 3
350
Frimley, London, Norwich, Oxford, Cottingham, Aberdeen, Birmingham, Glasgow
2026-05-14
Recruiting
Vertex Pharmaceuticals Incorporated
Phase 2
30
Birmingham, London, Salford
2026-05-13
Recruiting
Janssen Research & Development, LLC
Phase 1
360
Manchester
2026-05-13
Recruiting
Sarepta Therapeutics, Inc.
Phase 1
32
Cardiff
2026-05-12
Recruiting
Novo Nordisk A/S
Phase 3
5,610
Truro, Rhyl, Torquay, Dorchester, Airdrie, Tooting, Isleworth, Norwich
2026-05-11
Active, closed
Novartis Pharmaceuticals
Phase 3
5,700
Dorchester, London, Preston, Harrow, Rochdale, Portadown, Taunton, Chertsey
2026-05-11
Recruiting
A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies
NCT07613723Ovarian Cancer, Squamous Non-Small Cell Lung Cancer (NSCLC), Synovial Sarcomas, Head and Neck Cancer
DrugsFludarabine·Cyclophosphamide
Zelluna Immunotherapy AS
Phase 1
9
London, Manchester
2026-05-11
Recruiting
Incyte Corporation
Phase 1
218
London, Nottingham, Oxford
2026-05-11
Recruiting
Genmab
Phase 2
160
London
2026-05-11
Recruiting
UK PureWick™ At-Home Pilot Study
NCT07555548Urinary Incontinence
Becton, Dickinson and Company
Observational
95
Doncaster, Leicester, Northampton, Norwich
2026-05-06
Recruiting
AstraZeneca
Phase 2
24
Cambridge, London, Manchester
2026-05-06
Recruiting
EMD Serono Research & Development Institute, Inc.
Phase 3
1,020
Aberdeen, Manchester, London
2026-05-06
Recruiting
Hoffmann-La Roche
Phase 3
8
London
2026-05-06
Recruiting
Regeneron Pharmaceuticals
Phase 2
99
Bath, London
2026-05-06
Recruiting
Eli Lilly and Company
Phase 2
531
Cheadle, Hounslow, Macclesfield, Newcastle upon Tyne, Newquay, Rotherham, Surrey, Sutton in Ashfield
2026-05-06
Recruiting
Mirati Therapeutics Inc.
Phase 2
170
London, Birmingham, Leicester
2026-05-06
Recruiting
A. Menarini International Licensing S.A.
Phase 3
426
Stockton-on-Tees
2026-05-06
Recruiting
AstraZeneca
Phase 3
420
Edinburgh, Hampshire, Leeds, London, Manchester, Nottingham, Oxford, Sutton
2026-05-05
Recruiting
AstraZeneca
Phase 3
670
London, Middlesbrough, Southampton, Truro
2026-05-04
Recruiting
Merck Sharp & Dohme LLC
Phase 3
876
London, Swansea
2026-05-04
Recruiting
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
NCT07519772Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse
DrugMK-1045
Merck Sharp & Dohme LLC
Phase 1/2
280
Plymouth, Manchester
2026-05-03
Recruiting
LEO Pharma
Phase 3
652
Liverpool, London
2026-05-01
Recruiting
Altesa Biosciences, Inc.
Phase 2
180
Bromborough, Glasgow, London, Milton Keynes, Wolverhampton
2026-05-01
Recruiting
ALTO-207 in Adults With Treatment-resistant Depression (TRD)
NCT07553637Treatment-resistant Depression (TRD)
Alto Neuroscience
Phase 2
178
Antrim, Birmingham, Bristol, Cardiff, Exeter, London, Nottingham, Oxford
2026-05
Recruiting
Portal Therapeutics, Inc.
Observational
50
Cardiff, Dundee, London, Manchester
2026-04-30
Recruiting
AbbVie
Phase 2/3
900
Oxford
2026-04-30
Recruiting
Eli Lilly and Company
Phase 2
342
Cheadle, Hounslow, Macclesfield, Newcastle upon Tyne, Newquay, Rotherham, Surrey, Sutton in Ashfield
2026-04-29
Recruiting
Genentech, Inc.
Phase 1/2
260
Sutton
2026-04-29
Recruiting
Hoffmann-La Roche
Phase 3
360
London, Cardiff
2026-04-27
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
NCT07285655Pulmonary Hypertension Due to Lung Disease (Disorder)
Liquidia Technologies, Inc.
Phase 3
344
Bath, London, Plymouth, Sheffield
2026-04-23
Recruiting
Merck Sharp & Dohme LLC
Phase 3
590
Cambridge, London
2026-04-23
Recruiting
Inhibikase Therapeutics
Phase 3
486
Cambridge, Glasgow, London
2026-04-23
By invitation
QED Therapeutics, a BridgeBio company
Phase 2
135
Manchester, Sheffield, Glasgow
2026-04-23
Recruiting
BioNTech SE
Phase 3
736
Cambridge, London, Sutton
2026-04-22
Recruiting
Synendos Therapeutics AG
Phase 2
24
London
2026-04-22
Recruiting
Tessera Therapeutics, Inc.
Phase 1/2
72
London, Nottingham
2026-04-21
Recruiting
Janssen Research & Development, LLC
Phase 3
530
Greater London, Iselworth, London, Norwich, Wolverhampton
2026-04-21
Recruiting
Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma
NCT07346144Glioblastoma (GBM), High Grade Gliomas, Recurrent Glioblastoma, Newly Diagnosed Glioblastoma
Trogenix ltd
Phase 1/2
68
Edinburgh
2026-04-21
Active, closed
Novo Nordisk A/S
Phase 3
606
Macclesfield, Rotherham, Soham, Wellingborough
2026-04-21
Recruiting
Richmond Research Institute
Observational
100
London
2026-04-21
Recruiting
Pierian Biosciences
Observational
100
Liverpool
2026-04-21
Recruiting
Boehringer Ingelheim
Phase 2
405
Basingstoke, Belfast, Cambridge, Doncaster, London
2026-04-20
Recruiting
OLE Study With Filgotinib in JIA
NCT07553182Juvenile Idiopathic Arthritis (JIA)
DrugFilgotinib
Alfasigma S.p.A.
Phase 3
80
London
2026-04-20
Recruiting
BioMarin Pharmaceutical
Phase 2/3
160
Bristol, Glasgow, Liverpool, London, Manchester
2026-04-20
By invitation
BioMarin Pharmaceutical
Phase 2
18
London
2026-04-20
Recruiting
Calla Lily Clinical Care Ltd
Phase 1
20
Coventry
2026-04-20
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT07226843Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
DrugRituximab
Eli Lilly and Company
Phase 1
460
London, Nottingham, Plymouth, Southampton
2026-04-17
Recruiting
Visugromab in Cachexia International Trial
NCT07112196Cancer-associated Cachexia
DrugVisugromab
CatalYm GmbH
Phase 2/3
518
Brighton, Cambridge, Dundee, Edinburgh, Guildford, Manchester, Newcastle upon Tyne
2026-04-16
Recruiting
Mediar Therapeutics
Phase 2
85
Coventry, Liverpool, London, Westcliff-on-Sea
2026-04-16
Recruiting
Hoffmann-La Roche
Phase 3
100
Birmingham, Cambridge, Sheffield
2026-04-15
Recruiting
KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases
NCT06451757Mitochondrial Diseases, Maternally Inherited Diabetes and Deafness (MIDD), Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS), Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation
DrugSonlicromanol
Khondrion BV
Phase 3
220
London
2026-04-14
Recruiting
Gliknik Inc.
Phase 1
42
Leeds
2026-04-14
Recruiting
Eli Lilly and Company
Phase 2
60
London, Salford
2026-04-14
Recruiting
Controlling Hyperactive Immunity With Long-lived Lymphocytes
NCT07473154Diffuse Cutaneous Systemic Sclerosis, Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Autoimmune Rheumatologic Disease
Quell Therapeutics Limited
Phase 1/2
16
Birmingham, Leeds, London, Manchester, Newcastle, Oxford
2026-04-10
Recruiting
Merck Sharp & Dohme LLC
Phase 3
758
Cambridge, Edinburgh, Glasgow, Leicester, Withington, Birmingham, Cardiff, Southampton
2026-04-09
Recruiting
Incyte Corporation
Phase 3
588
Dundee, Guildford, Headington, Leeds, London, Manchester, Northwood, Norwich
2026-04-09
Recruiting
Prospective Follow-up of the Prevision Hip Stem With Comparison of Different Implant Variants
NCT06626490Revision Total Hip Arthroplasty, Periprosthetic Fracture of Hip
Aesculap AG
Observational
120
Huntingdon
2026-04-07
Recruiting
A Gaucher Disease Gene Therapy Trial With FLT201
NCT07223944Gaucher Disease Type 1
Spur Therapeutics
Phase 3
45
Birmingham, Salford, London, Cambridge
2026-04-07
Recruiting
Boston Scientific Corporation
Observational
200
Coventry
2026-04-07
Recruiting
Hoffmann-La Roche
Phase 2
80
Leicester, London, Manchester
2026-04-07
Active, closed
The Effects of PeptiStrong and Whey on Muscle Function In Older Adults
NCT07528469Healthy Ageing, Protein Supplementation, Muscle Health, Muscle Function
Nuritas Ltd
Not applicable
81
Liverpool
2026-04-06
Recruiting
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
NCT07428499Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, HAE
ADARx Pharmaceuticals, Inc.
Phase 3
90
Cambridge, Cardiff, London, Southampton
2026-04-02
Active, closed
Pfizer
Observational
4,000
Tadworth
2026-04-01
Recruiting
EMD Serono Research & Development Institute, Inc.
Phase 3
202
Doncaster
2026-04-01
Not yet open
Indizen Optical Technologies, S.L.U.
Observational
180
Coleraine
2026-04
Recruiting
Octapharma
Phase 4
28
Leeds
2026-04
Recruiting
Comprehensive LEFt Atrial Appendage Occlusion With Rhythm Restoration
NCT07523620Atrial Fibrillation (AF), Paroxysmal AF, Persistent Atrial Fibrillation
Abbott Medical Devices
Not applicable
240
Brighton, Oxford
2026-03-31
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
118
Edinburgh, London
2026-03-31
Recruiting
AstraZeneca
Phase 1
104
Harrow
2026-03-30
Recruiting
PS-002 for the Treatment of IgA Nephropathy in Adults
NCT07182227Immunoglobulin A (IgA) Nephropathy
Purespring Therapeutics Limited
Phase 1/2
32
Manchester, Leicester, Nottingham, Bristol, Cardiff, Edinburgh, London
2026-03-30
Recruiting
Renaissance Pharma Ltd.
Phase 2/3
144
Southampton, Sutton
2026-03-30
Recruiting
AstraZeneca
Phase 2
43
London, Manchester
2026-03-28
Recruiting
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
NCT07440225Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
DrugsTiespectus·Eylea·Aflibercept
EyeBiotech Ltd.
Phase 2/3
960
Leicester, Liverpool, London
2026-03-27
Recruiting
Bristol-Myers Squibb
Phase 1/2
474
London, Preston, Cambridge, Cardiff, Edinburgh, Manchester, Sulton, Surrey
2026-03-26
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 1
48
London
2026-03-26
Recruiting
Transition to KPL-387 Monotherapy Dosing & Administration Study
NCT07288216Recurrent Pericarditis, Heart Diseases, Pericarditis
DrugKPL-387
Kiniksa Pharmaceuticals International, plc
Phase 2
120
London
2026-03-25
Recruiting
Bristol-Myers Squibb
Phase 3
325
Exeter, London, Oxford, Chertsey, Sheffield, Crowborough, Motherwell
2026-03-25
Recruiting
JCR Pharmaceuticals Co., Ltd.
Observational
57
Belfast, Birmingham, London, Manchester, Salford
2026-03-25
Recruiting
Merck Sharp & Dohme LLC
Phase 2
100
Cambridge, Bury, London, Huddersfield
2026-03-24
Recruiting
Novartis Pharmaceuticals
Phase 3
770
Exeter, Aberdeen, Cambridge, Cardiff, Glasgow, Leeds, London, Oxford
2026-03-24
Active, closed
ModernaTX, Inc.
Phase 3
4,050
Bristol, High Wycombe, Peterborough, Stockton-on-Tees, Bournemouth, Weymouth, Glasgow, Enfield
2026-03-23
Recruiting
Merck Sharp & Dohme LLC
Phase 3
450
Glasgow, London, Manchester
2026-03-23
Recruiting
Boehringer Ingelheim
Phase 2
132
Bradford, London, Salford
2026-03-23
Recruiting
Hoffmann-La Roche
Phase 3
1,600
Blackpool, Aberdeen, Antrim, Bristol, Dundee, Hounslow, Hull, Nuneaton
2026-03-23
Recruiting
GlaxoSmithKline
Phase 1
97
Cambridge, Edinburgh
2026-03-23
Recruiting
Quoin Pharmaceuticals
Phase 2/3
16
London, Walsall
2026-03-19
Recruiting
Priovant Therapeutics, Inc.
Phase 2/3
342
Salford, Glasgow, Brighton, London, Wrexham
2026-03-19
Recruiting
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
NCT07219459Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
DrugsVisugromab RDE·Visugromab·Opdivo·Lenvatinib
CatalYm GmbH
Phase 2
104
Edinburgh, London
2026-03-19
Recruiting
Santen SAS
Observational
112
London
2026-03-19
Recruiting
Merck Sharp & Dohme LLC
Phase 3
400
London, Portsmouth
2026-03-18
Recruiting
SymBio Pharmaceuticals
Phase 3
180
Birmingham, Leeds, London, Manchester, Newcastle upon Tyne, Sheffield, Sutton
2026-03-17
Recruiting
AstraZeneca
Phase 1/2
180
Cambridge, London, Sutton
2026-03-17
Recruiting
AIRNA Corporation
Phase 1
54
Cambridge, London, Southampton
2026-03-17
Recruiting
Hoffmann-La Roche
Phase 3
2,000
Soham, Chippenham, Airdrie, Birmingham, Glasgow, Leicester, London, Newcastle upon Tyne
2026-03-16
Recruiting
Bristol-Myers Squibb
Phase 3
850
Manchester, Newcastle upon Tyne, Birmingham, Cambridge, Cardiff, Guildford, Leeds, Liverpool
2026-03-16
Recruiting
Sanofi
Observational
60
Birmingham, London
2026-03-16
Recruiting
Bristol-Myers Squibb
Phase 1/2
198
London, Glasgow, Metropolitan Borough of Wirral
2026-03-16
Not yet open
BAIBYS Fertility
Not applicable
260
Manchester
2026-03-15
Recruiting
Bristol-Myers Squibb
Phase 2/3
690
London, Oxford, Sutton, Glasgow, Manchester
2026-03-13
Recruiting
Sanofi
Phase 2/3
526
Birmingham
2026-03-13
Recruiting
GlaxoSmithKline
Phase 3
456
Bradford
2026-03-13
Active, closed
Sanofi
Phase 3
59
Wigan, London, Bradford
2026-03-12
Recruiting
Bristol-Myers Squibb
Phase 3
750
Aberdeen, Middlesbrough, Norwich, Sutton, Cambridge, Cardiff, Guildford, London
2026-03-12
Recruiting
Astellas Pharma Global Development, Inc.
Phase 2
240
London
2026-03-12
Active, closed
Boehringer Ingelheim
Phase 1
80
Nottingham
2026-03-11
Recruiting
Hoffmann-La Roche
Phase 2
100
Sutton, Cardiff
2026-03-11
Recruiting
Hemab ApS
Phase 2
18
London
2026-03-11
Recruiting
Avalyn Pharma Inc.
Phase 2
160
Exeter, Cottingham, Leicester, Birmingham
2026-03-10
Active, closed
Europa Life Sciences Limited
Not applicable
6
Royal Tunbridge Wells
2026-03-10
Recruiting
Hoffmann-La Roche
Phase 2
360
Truro, London, Glasgow, Cardiff, Salford, Swansea
2026-03-10
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
DrugsCetuximab·Nab-paclitaxel·Gemcitabine
Revolution Medicines, Inc.
Phase 3
900
Torquay, Birmingham, Cambridge, Liverpool, London, Manchester
2026-03-09
Recruiting
Novartis Pharmaceuticals
Phase 2
272
Bristol, London, Newcastle upon Tyne, Southampton
2026-03-09
Recruiting
Eli Lilly and Company
Phase 4
150
Hull, Leeds, Newmarket
2026-03-09
Active, closed
EasiVits Acceptability & Tolerance Study
NCT07619170Inborn Errors of Metabolism
NeoteriQ Ltd.
Not applicable
30
Birmingham
2026-03-07
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Bath, Cambridge, Greater London, Newcastle upon Tyne, Peterborough, Reading, Southampton, Stoke-on-Trent
2026-03-05
Recruiting
Incyte Corporation
Phase 3
700
Bristol, Cardiff, Leeds, London, Maidstone, Manchester, Sutton
2026-03-05
Recruiting
EU Post-Market Registry to Collect Real-World Clinical Data on the Use of the Histolog Scanner.
NCT07006090Adult Patients Undergoing a Surgery or a Medical Procedure With Use of Histolog® Scanner, Whatever the Disease Area
SamanTree Medical SA
Observational
5,000
Guildford
2026-03-04
Recruiting
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
NCT07288398Pulmonary Hypertension Associated With HFpEF
DrugTNX-103
Tenax Therapeutics, Inc.
Phase 3
540
Cambridge, Glasgow, London, Sheffield, Swindon
2026-03-03
Recruiting
Study of TGM-312-SC01 in Healthy Participants and Adults With MASH
NCT07427680Healthy Participants, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Tangram Therapeutics Plc
Phase 1/2
99
London
2026-03-03
Recruiting
Abivax S.A.
Phase 1
44
Nottingham
2026-03-03
Recruiting
Alnylam Pharmaceuticals
Phase 1
44
London
2026-03-02
Recruiting
Kortuc, Inc.
Phase 1
70
Manchester
2026-03-01
Not yet open
Axon Therapies, Inc.
Not applicable
50
Leeds, London
2026-03-01
Active, closed
Bristol-Myers Squibb
Observational
300
London
2026-02-28
Recruiting
Mirum Pharmaceuticals, Inc.
Phase 2/3
120
Cottingham, Cardiff, London, Manchester
2026-02-26
Active, closed
Pfizer
Phase 3
1,078
Hendon, Glasgow, Bellshill, Birmingham, Bristol, Bromborough, Edgbaston, Enfield
2026-02-24
Recruiting
Novo Nordisk A/S
Phase 3
1,150
Fowey, Poole, Macclesfield, Pickering, Addlestone, Bradford on Avon, Hounslow, Nantwich
2026-02-24
Recruiting
AstraZeneca
Phase 3
508
Birmingham, Bristol, Glasgow, Scotland, London
2026-02-23
Active, closed
Philip Morris Products S.A.
Not applicable
108
Belfast
2026-02-19
Recruiting
Hoffmann-La Roche
Phase 2
80
Blackpool, Harlow, Northwood, Middlesex, Oxford
2026-02-18
Recruiting
C4 Therapeutics, Inc.
Phase 2
100
London
2026-02-18
Recruiting
Astellas Pharma Global Development, Inc.
Phase 3
614
Cambridge, Cottingham, Ipswich, London, Maidstone, Sutton
2026-02-17
Recruiting
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
NCT07335497Locally Advanced / Metastatic Solid Tumors
Crescent Biopharma, Inc.
Phase 1/2
290
Manchester
2026-02-17
Recruiting
Neurocrine Biosciences
Phase 2
120
London, Oxford
2026-02-16
Recruiting
Merck Sharp & Dohme LLC
Phase 3
900
Bath, Cambridge, Leicester, London, Manchester
2026-02-16
Recruiting
Boehringer Ingelheim
Phase 3
286
Bebington, Bradford, Cambridge, Carshalton, Leicester, London, Middlesbrough, Salford
2026-02-16
Recruiting
Kardigan, Inc.
Phase 2/3
332
Bristol, Glasgow, Leicester, London, Oxford
2026-02-13
Recruiting
Eli Lilly and Company
Phase 2
465
Chertsey, Doncaster, Eastbourne, Glasgow, London, Manchester, Milton Keynes, Southampton
2026-02-13
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
24
Leeds, London
2026-02-11
Recruiting
A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
NCT07201922Familial Pulmonary Fibrosis, Interstitial Lung Abnormalities, Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
80
Exeter, London
2026-02-10
Recruiting
Promedius Inc
Observational
595
Westcliff-on-Sea, London
2026-02-10
Recruiting
AstraZeneca
Phase 2
124
Brighton, Guildford, Liverpool, London
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
900
Bristol, Glasgow, London, Newcastle, Penzance, Rotherham, Sheffield, York
2026-02-09
Recruiting
Novo Nordisk A/S
Phase 1
100
Harrow
2026-02-09
Not yet open
The Concert Therapy for Stress Regulation in a Non-Clinical Adult Population
NCT07430631Stress Regulation and Well-being in Non-clinical Contexts
Behnam Khodarahmi
Not applicable
150
London
2026-02-09
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
55
London
2026-02-09
Recruiting
Chong Kun Dang Pharmaceutical
Phase 1
519
London
2026-02-09
Recruiting
RIG 101 Trial in Healthy Adults and Adults With Asthma
NCT07488897Healthy Adult Participants, Asthma Exacerbation, Safety and Efficacy
RIGImmune Inc.
Phase 1/2
82
London, Manchester
2026-02-09
Recruiting
Eli Lilly and Company
Phase 3
1,000
Edinburgh, Exeter, Glasgow, London, Nottingham, Oxford, Penzance, Rotherham
2026-02-09
Recruiting
Surgical Procedure Efficiency Evaluation stuDy
NCT07228091Cataract, Vitreous Hemorrhage, Retinal Detachment, Macular Pucker
Alcon Research
Observational
180
Manchester
2026-02-09
Recruiting
SYSNAV
Observational
140
London
2026-02-06
Recruiting
Eli Lilly and Company
Phase 3
1,980
Blackpool, Bradford on Avon, Lancashire, Lancaster, Londonderry, Manchester, Peterborough, Romsey
2026-02-06
Recruiting
Respiration From Pleth Validation
NCT07449715Respiratory Rate Monitoring
Philips Clinical & Medical Affairs Global
Observational
113
Bangor
2026-02-06
Recruiting
Eli Lilly and Company
Phase 3
300
Aberdeen, Birmingham, Bristol, Cambridge, Cardiff, Oxford, Southampton
2026-02-05
Recruiting
Janssen Research & Development, LLC
Phase 3
400
Canterbury, Cardiff, Dundee, London, Nottingham, Portsmouth, Sutton
2026-02-04
Recruiting
Peptilogics
Phase 2/3
240
Cambridge, Edinburgh, Norwich, Leeds
2026-02-03
Recruiting
Alnylam Pharmaceuticals
Phase 3
125
London
2026-02-03
Recruiting
Early Feasibility Clinical Investigation to Assess YntraDose™ as a Neoadjuvant Treatment for LA-PDAC
NCT07155850Pancreatic Ductal Adenocarcinoma (PDAC), Locally Advanced, Unresectable
BetaGlue Therapeutics SpA
Not applicable
10
London
2026-02-03
Recruiting
AstraZeneca
Phase 3
2,130
Cambridge, Dundee, Leeds, London, Manchester, Oxford
2026-02-03
Recruiting
CSL Behring
Phase 2
63
London
2026-02-02
Active, closed
LIQUIBAND FIX8® for Ventral Incisional Hernia
NCT07295379Hernia Incisional Ventral
Advanced Medical Solutions Ltd.
Observational
148
Lancaster
2026-02-02
Recruiting
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
NCT06968845Idiopathic Pulmonary Fibrosis (IPF)
Rein Therapeutics
Phase 2
120
Birmingham, Edgbaston, Trumpington, Exeter, Oxford, Edinburgh, London
2026-02-02
Recruiting
Exciva GmbH
Phase 2/3
300
Edinburgh, Aberdeen
2026-02-02
Recruiting
Prilenia
Phase 3
500
London, Stoke-on-Trent
2026-02-01
Not yet open
International Study on Treatment of Liver (HCC) Patients With IRE
NCT07192731Hepatocellular Carcinoma (HCC), Liver Ablation, Liver Cancer, Adult
Angiodynamics, Inc.
Not applicable
50
Manchester
2026-02
Not yet open
International Study on Treatment of Patients With Metastatic Colorectal Liver Lesions Patients With IRE
NCT07191548Colorectal Adenocarcinoma Metastatic in the Liver, Liver Ablation, Liver Cancer, Adult
Angiodynamics, Inc.
Not applicable
50
Manchester
2026-02
Recruiting
Denali Therapeutics Inc.
Phase 1
68
London
2026-01-30
Recruiting
Calcilytix Therapeutics, Inc., a BridgeBio company
Phase 2/3
28
London, Manchester
2026-01-30
Active, closed
Bayer
Observational
1,600
Multiple Locations
2026-01-29
Recruiting
Dentsply Sirona Implants and Consumables
Not applicable
90
Bexleyheath
2026-01-29
Recruiting
Kymera Therapeutics, Inc.
Phase 2
264
Bedford, Birmingham, Bristol, Leicester, London, Wythenshawe
2026-01-28
Active, closed
Glyconics Ltd
Not applicable
100
Ashton-under-Lyne, London
2026-01-28
Active, closed
Hoffmann-La Roche
Phase 1
6
London, Southampton, Glasgow
2026-01-27
Active, closed
AstraZeneca
Phase 1/2
6
Cambridge
2026-01-27
By invitation
Immunovant Sciences GmbH
Phase 2
372
Truro
2026-01-26
Recruiting
IDEAYA Biosciences
Phase 3
520
Metropolitan Borough of Wirral, London, Sheffield
2026-01-25
Recruiting
AbbVie
Phase 2
165
Cambridge, Edinburgh, London, Southampton, Norwich
2026-01-23
Recruiting
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
NCT07096778Multiple Myeloma Refractory, Multiple Myeloma in Relapse
DrugsPomalidomide·Dexamethasone
CellCentric Ltd.
Phase 2
100
Withington, Sutton, Cardiff, Bebington, Edinburgh, London, Oxford, Southampton
2026-01-22
Recruiting
CSL Behring
Phase 2
84
Glasgow, Belfast, Bristol, Liverpool, London, Norwich, Nottingham, Oxford
2026-01-22
Recruiting
BeOne Medicines
Phase 3
500
Birmingham, Bournemouth, Leeds, London, Norwich
2026-01-22
Recruiting
City Therapeutics
Phase 1
182
London
2026-01-22
Recruiting
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
NCT07159841Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
DrugAtumelnant
Crinetics Pharmaceuticals Inc.
Phase 2/3
153
Liverpool, London, Manchester, Sheffield
2026-01-22
Recruiting
Generate Biomedicines
Phase 3
786
High Wycombe, Ashburton, Bristol, London, Romford, Rotherham, Thetford, Nottingham
2026-01-20
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,023
Edinburgh, Truro, London, Withington
2026-01-19
Recruiting
Autolus Limited
Phase 2
35
Birmingham, Bristol, Cambridge, Edinburgh, Glasgow, London, Manchester
2026-01-16
Recruiting
Boehringer Ingelheim
Phase 3
400
Cardiff, Edinburgh, London, Manchester, Sutton
2026-01-16
Recruiting
Bristol-Myers Squibb
Observational
362
Bollington
2026-01-15
Recruiting
Celldex Therapeutics
Phase 3
240
Cambridge, Glasgow, Manchester
2026-01-15
Recruiting
Takeda
Phase 3
183
Exeter, Colcester, Gloucester, Cardiff, Milton Keynes, Stafford
2026-01-14
Recruiting
Janssen Research & Development, LLC
Phase 1
40
Manchester, Sutton
2026-01-14
Recruiting
Novartis Pharmaceuticals
Phase 1/2
181
London
2026-01-13
Active, closed
EveryONE Medicines Inc.
Phase 1/2
1
London
2026-01-13
Recruiting
ConvaTec Inc.
Not applicable
87
Bollington, Knutsford, Dorchester, Swaffham, Ashington, Nottingham
2026-01-12
Recruiting
Eli Lilly and Company
Phase 3
150
Birmingham, Cambridge, Cardiff, Glasgow, London, Oxford, Southampton
2026-01-12
Active, closed
Kailera
Phase 3
1,270
Truro, Plymouth, Bournemouth, Hull, Glasgow, London, Stevenage, Leicester
2026-01-12
Recruiting
A Study of AZD0120 in Autoimmune Diseases
NCT07295847Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
DrugAZD0120
AstraZeneca
Phase 1
27
Edinburgh, London
2026-01-09
Recruiting
AstraZeneca
Phase 1/2
84
Edinburgh, London, Manchester, Newcastle
2026-01-09
Recruiting
Contineum Therapeutics
Phase 2
324
Leicester, London, Southampton, Edinburgh, Perth, Birmingham
2026-01-08
Recruiting
Amicus Therapeutics
Phase 3
8
London, Manchester
2026-01-08
Recruiting
Novo Nordisk A/S
Phase 3
460
Birmingham, Liverpool, London
2026-01-08
Recruiting
Insmed Incorporated
Phase 3
344
London, Sheffield, Bath, Belfast, Glasgow, Salford, Southampton
2026-01-07
By invitation
Medtronic
Observational
2,000
Liverpool, London, Southampton
2026-01-07
Recruiting
Syantra Inc.
Observational
2,000
Manchester
2026-01-07
Recruiting
Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder
NCT07224581GRIN-related Neurodevelopmental Disorder
DrugRadiprodil
GRIN Therapeutics, Inc.
Phase 3
100
Sheffield, Glasgow, London
2026-01-05
Recruiting
Regeneron Pharmaceuticals
Phase 3
915
Aberdeen, Truro, Plymouth, Norwich, Birmingham, Dundee
2026-01-02
Recruiting
Bristol-Myers Squibb
Phase 2/3
590
Leicester, London
2026-01-02
Recruiting
Theradex
Phase 2
66
London, Manchester
2026-01-01
Recruiting
Plant-Protein Dominant Tube Feed Study
NCT07422935Enteral Nutrition (Food for Special Medical Purposes), Enteral Feeds
Nutricia UK Ltd
Not applicable
110
Trowbridge
2026-01-01
Recruiting
Bristol-Myers Squibb
Phase 2/3
990
Norwich, Manchester, Metropolitan Borough of Wirral, Oxford, Guildford, Birmingham, Cardiff, Dorchester
2025-12-31
Recruiting
Complement Therapeutics
Phase 1/2
75
Gloucester, London, Sunderland
2025-12-30
Active, closed
Kailera
Phase 3
1,270
Exeter, Torquay, Weymouth, Glasgow, London, Leicester, Rotherham
2025-12-30
Active, closed
UCB Biopharma SRL
Phase 2
165
London, Salford
2025-12-29
Recruiting
Incyte Corporation
Phase 2
56
Cottingham, London, Plymouth
2025-12-29
Recruiting
AstraZeneca
Phase 3
1,100
Barrow in Furness, Birmingham, Cambridge, Canterbury, Cardiff, Edinburgh, Greater London, London
2025-12-29
Recruiting
Norgine
Phase 3
212
Edinburgh, Newcastle upon Tyne, Sheffield, London, Birmingham
2025-12-29
By invitation
Wave Life Sciences USA, Inc.
Phase 2
175
Headington
2025-12-28
Recruiting
Galmed Pharmaceuticals Ltd
Phase 1
32
London
2025-12-25
Active, closed
Clinical Performance Evaluation of the QIAstat-Dx® cUTI Plus AMR
NCT06824129Complicated Urinary Tract Infection
QIAGEN Gaithersburg, Inc
Observational
1,500
Manchester
2025-12-23
Recruiting
Taiho Oncology, Inc.
Phase 3
360
Manchester, Nottingham, Torquay, Cardiff
2025-12-22
Recruiting
nChroma Bio
Phase 1/2
66
London
2025-12-22
Recruiting
Eli Lilly and Company
Phase 3
800
Edinburgh, Huddersfield, London, Manchester, Plymouth, Worcester
2025-12-22
Recruiting
Javier Toledo
Observational
6,000
Cambridge, London
2025-12-20
Recruiting
Safety, Performance, and Clinical Benefit of Pacing the Left Bundle Branch Area - Post-Market Clinical Follow-up
NCT07209852Bradycardia, Atrioventricular Block, Sinus Node Dysfunction, Bundle-Branch Block
Boston Scientific Corporation
Observational
140
Redhill
2025-12-19
Recruiting
argenx
Phase 2
60
Cambridge, London, Oxford, Sheffield, Glasgow, Birmingham, Leeds
2025-12-19
Recruiting
A Study to Evaluate the Safety and Effectiveness of the Rapidlink Device When Used in Patients Undergoing an Open Surgical Procedure to Repair the Aorta
NCT07078383Aortic Aneurysm, Aortic Aneurysm and Dissection, Aortic Diseases, Aneurysm of Aorta, Thoracic
Vascutek Ltd.
Not applicable
150
London
2025-12-19
Recruiting
Janssen Research & Development, LLC
Phase 3
800
Cardiff, Glasgow, London, Newcastle upon Tyne, Preston, Sutton
2025-12-19
Recruiting
Vector Y Therapeutics
Phase 1/2
12
London, Sheffield
2025-12-19
Active, closed
Pfizer
Phase 3
3,578
Sandbach, Hendon, Glasgow, Bellshill, Birmingham, Bristol, Bromborough, Edgbaston
2025-12-19
Recruiting
Heartfelt Technologies
Not applicable
300
Aylesbury, Croydon, Welwyn Garden City, Patrington, Ashford, Lincoln, Hardwick, Belfast
2025-12-18
Active, closed
Kailera
Phase 3
2,530
Soham, Torpoint, Hull, Stevenage, Leicester, Nottingham, Newcastle upon Tyne, Bradford
2025-12-18
Recruiting
Initiator Pharma
Phase 2
24
Blackpool
2025-12-17
Recruiting
ArriVent BioPharma, Inc.
Phase 3
480
London, Manchester
2025-12-17
Recruiting
Chiesi Farmaceutici S.p.A.
Phase 2
780
Belfast, Bristol, Dagenham, London, Maidstone, Manchester, Orpington, Portsmouth
2025-12-17
Recruiting
A Study on Hemolytic Disease of the Fetus and Newborn (HDFN) Through Global Registry
NCT07194070Hemolytic Disease of the Fetus and Newborn
Janssen Research & Development, LLC
Observational
175
Birmingham
2025-12-17
Recruiting
Draig Therapeutics Ltd
Phase 2
300
Chester, Eastbourne, Glasgow, London, Nottingham, Oxford
2025-12-16
Recruiting
Diabetis JSC
Observational
100
Blackpool, Lancaster, Manchester
2025-12-16
Recruiting
AstraZeneca
Phase 2
320
Glasgow, Leeds, Luton, Staffordshire
2025-12-15
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
DrugCetuximab
Revolution Medicines, Inc.
Phase 3
500
Birmingham, Glasgow, Liverpool, London, Manchester
2025-12-15
Recruiting
Novartis Pharmaceuticals
Observational
3,000
London
2025-12-15
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Huddersfield, London, Manchester, Sheffield
2025-12-12
Recruiting
Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN)
NCT07072468Chemotherapy-induced Peripheral Neuropathy, Drug-Induced Nephropathy
VM Therapeutics LLC
Phase 2
16
London
2025-12-12
Recruiting
Angitia Incorporated Limited
Phase 2
80
Cambridge, Edinburgh, London, Oxford
2025-12-12
Recruiting
Alnylam Pharmaceuticals
Phase 1
76
London
2025-12-12
Active, closed
Zealand Pharma
Phase 3
28
Ealing
2025-12-11
Recruiting
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
NCT07144163Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
DrugAtumelnant
Crinetics Pharmaceuticals Inc.
Phase 3
150
Cardiff, London, Manchester, Sheffield
2025-12-11
Recruiting
Société des Produits Nestlé (SPN)
Not applicable
50
Nottingham, Worcester
2025-12-10
Recruiting
Pfizer
Phase 3
32,500
Newquay, Exeter, Plymouth, Torquay, Preston, Glasgow, Southampton, Blackpool
2025-12-10
Recruiting
AstraZeneca
Phase 2
230
Birmingham, Cambridge, Cardiff, Newcastle
2025-12-10
Recruiting
ALX Oncology Inc.
Phase 2
120
London, Cardiff, Nottingham
2025-12-10
Recruiting
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
NCT06793397Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders
DrugCYB003
Cybin IRL Limited
Phase 3
330
Cambridge, Doncaster, Edinburgh, Glasgow, London, Newcastle upon Tyne, Reading, Sheffield
2025-12-10
Recruiting
AbbVie
Phase 2/3
490
London, Manchester
2025-12-10
Recruiting
Incyte Corporation
Phase 3
466
Cambridge, Cardiff, Guildford, Leeds, Liverpool, London, Manchester Greater, Northampton
2025-12-09
Recruiting
AstraZeneca
Phase 1
24
Cambridge, London
2025-12-09
Active, closed
Boehringer Ingelheim
Phase 3
135
Birmingham, Bristol, Glasgow, Liverpool, London, Newcastle upon Tyne, Nottingham, Southampton
2025-12-09
Active, closed
Effects of a Multi-Targeted Oral Supplement on Skin, Hair, Sleep, Energy, Cognition, Libido and Epigenetic Biological Clock Age
NCT07827651Skin Ageing, Healthy Ageing, Effect of Oral Nutritional Supplementation on Skin, Hair, Sleep, Energy, Cognition and Sexual Wellbeing in Healthy Adults, Longevity
IDI Skincare Limited
Not applicable
64
Edinburgh
2025-12-08
Active, closed
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
NCT07287189Duchenne Muscular Dystrophy, Duchenne, DMD, Neuromuscular Diseases
DrugSAT-3247
Satellos Bioscience, Inc.
Phase 2
51
London
2025-12-08
Active, closed
UCB Biopharma SRL
Phase 1
80
Harrow
2025-12-08
Recruiting
Hoffmann-La Roche
Phase 2
160
Leicester, Doncaster, Newcastle upon Tyne, Barnet
2025-12-05
Active, closed
AstraZeneca
Phase 2
222
Dundee, Liverpool, London
2025-12-05
Recruiting
Merck Sharp & Dohme LLC
Phase 2
150
London, Manchester
2025-12-04
Recruiting
AstraZeneca
Phase 3
1,100
Birmingham, Glasgow, Greater London, Leeds, London, Manchester
2025-12-04
Recruiting
GlaxoSmithKline
Phase 1
83
Leicester, London, Sutton
2025-12-03
Recruiting
Janssen Research & Development, LLC
Observational
380
Bath, Cardiff, Eastbourne, Guildford, Heath Town, London, Manchester, Sutton
2025-12-03
Recruiting
Janssen Research & Development, LLC
Phase 3
500
Cambridge, Cottingham, Edinburgh, Greater London, Guildford, London, Metropolitan Borough of Wirral, Northwood
2025-12-03
Recruiting
GlaxoSmithKline
Phase 3
450
Manchester, Edinburgh, Cambridge, Leeds, London, Sheffield
2025-12-03
Recruiting
Bristol-Myers Squibb
Phase 3
650
Preston, Chertsey, Cambridge, London, Motherwell, Redruth, Sheffield, Stafford
2025-12-02
Recruiting
Sanofi
Phase 2
37
Newcastle upon Tyne, London
2025-12-02
Recruiting
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
NCT07201558Rheumatoid Arthritis, Systemic Lupus Erythematosus
DrugSurovatamig
AstraZeneca
Phase 1
48
London
2025-12-02
Recruiting
Eli Lilly and Company
Phase 3
7,140
Birmingham, Blackpool, Bromborough, Newcastle, Newquay, Poole, Rotherham, Torpoint
2025-12-01
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 3
480
Cambridge, London, Chelsea, Sutton, Stoke-on-Trent, Nottingham, Wolverhampton
2025-11-30
Recruiting
Amgen
Phase 3
750
London, Sutton
2025-11-28
Active, closed
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
NCT07288203Melanoma (Skin Cancer), Unresectable Melanoma, Metastatic Melanoma
DrugLifileucel
Iovance Biotherapeutics, Inc.
Phase 2
24
London
2025-11-28
Recruiting
Hoffmann-La Roche
Phase 3
250
Leicester, Gloucester, London
2025-11-27
Recruiting
Debiopharm International SA
Phase 3
119
Birmingham, Leeds
2025-11-26
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 2
75
Birmingham, Cambridge, Leicester, London, Manchester
2025-11-26
Recruiting
Merck Sharp & Dohme LLC
Phase 3
904
Cambridge
2025-11-26
Recruiting
SAb Biotherapeutics, Inc.
Phase 2
159
Cambridge, Cardiff, Edinburgh, Liverpool, London, Nottingham, Oxford
2025-11-25
Recruiting
AstraZeneca
Phase 1
40
Newcastle upon Tyne, Sutton
2025-11-25
Recruiting
Syndax Pharmaceuticals
Phase 3
468
Oxford, Aberdeen, Derby, Lincoln, London, Southampton, Sutton
2025-11-25
By invitation
Celldex Therapeutics
Phase 3
1,370
Leeds, Bristol, Cambridge, Glasgow, North Finchley
2025-11-25
Recruiting
AstraZeneca
Phase 4
56
Harefield, London, Manchester
2025-11-24
Recruiting
TrueLok Elevate PMCF Study
NCT07079774Wound of Skin, Ulcers, Soft Tissue Defect
Orthofix s.r.l.
Observational
153
Hull, Newcastle upon Tyne
2025-11-24
Recruiting
Hoffmann-La Roche
Phase 3
900
Dundee, Exeter, London, Newcastle, Oxford, Plymouth,Devon
2025-11-24
Recruiting
Eli Lilly and Company
Phase 4
3,000
Altrincham, Ashton-under-Lyne, Bolton, Bury, Cheshire, Great Lever, Hyde SK14, Manchester
2025-11-24
Active, closed
Hoffmann-La Roche
Phase 1
3
Cambridge
2025-11-19
Recruiting
QED Therapeutics, a BridgeBio company
Phase 2
77
Glasgow, Manchester, Sheffield
2025-11-19
Recruiting
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
NCT07087054Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum
Crinetics Pharmaceuticals Inc.
Phase 3
141
London, Oxford, Birmingham, Cardiff, Glasgow, Sheffield, Southampton
2025-11-19
Active, closed
Bayer
Phase 2
60
Exeter, London, Sheffield, Sunderland
2025-11-19
Recruiting
XEOS Medical
Observational
850
Coventry
2025-11-19
Recruiting
Bayer
Phase 3
111
Leicester, Liverpool, Belfast, Glasgow, Newcastle upon Tyne, Leeds, Bristol
2025-11-19
Active, closed
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
NCT07161037Autosomal Dominant Polycystic Kidney Disease (ADPKD)
DrugVX-407
Vertex Pharmaceuticals Incorporated
Phase 2
26
Birmingham, London, Newcastle upon Tyne, Sheffield
2025-11-19
Recruiting
BioNTech SE
Phase 1/2
245
Leeds, London, Manchester, Newcastle upon Tyne, Sutton
2025-11-18
Recruiting
Summit Therapeutics
Phase 3
600
Canterbury, London, Aberdeen, Edinburgh, Liverpool, Manchester
2025-11-18
Recruiting
Janssen-Cilag Ltd.
Observational
220
Harrow
2025-11-17
Recruiting
iOnctura
Phase 1/2
26
Boston, Belfast, London
2025-11-17
Active, closed
Eli Lilly and Company
Phase 3
250
Birmingham, Blackpool, Bradford on Avon, Bromborough, Cheadle, Hounslow, Oxford, Penzance
2025-11-17
Active, closed
Pfizer
Observational
250
London
2025-11-15
Recruiting
UCB Biopharma SRL
Phase 3
320
London, Salford
2025-11-14
Recruiting
Prima Mente
Observational
1,000
London, Newport, Bradford, Bridgend, Llanelli, Newcastle upon Tyne, Penarth, Reading
2025-11-13
Recruiting
Incyte Corporation
Phase 3
250
London, Sheffield, Walsall
2025-11-13
Active, closed
Hoffmann-La Roche
Phase 3
1,060
Bath, Birmingham, Edinburgh, Glasgow, London, Manchester, Oxford, Preston
2025-11-12
Recruiting
AstraZeneca
Phase 1/2
83
Bloomsbury, Manchester
2025-11-12
Recruiting
Incyte Corporation
Phase 2
160
London, Manchester Greater
2025-11-12
Active, closed
Merck Sharp & Dohme LLC
Phase 3
996
Bristol, Yate, London, Corby
2025-11-11
Recruiting
Novartis Pharmaceuticals
Phase 3
1,275
Brighton, Romford, Bristol, Coventry, Glasgow, Leeds, London, Nottingham
2025-11-11
Active, closed
AstraZeneca
Phase 1
19
Ruddington
2025-11-11
Recruiting
AstraZeneca
Phase 3
420
Glasgow, Scotland, London, Manchester, Newcastle upon Tyne, Nottingham
2025-11-11
Recruiting
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
NCT06990269Geographic Atrophy Secondary to Age-related Macular Degeneration
ADARx Pharmaceuticals, Inc.
Phase 2
240
Liverpool, Dorchester, Wolverhampton, London, Sunderland
2025-11-10
Recruiting
AstraZeneca
Phase 1
40
London
2025-11-10
By invitation
Rhythm Pharmaceuticals, Inc.
Phase 2
25
Birmingham, Cambridge, London
2025-11-10
Active, closed
Pfizer
Phase 2
42
London
2025-11-10
Recruiting
Boehringer Ingelheim
Phase 3
670
Cardiff, Leicester, Manchester, Sutton, Torquay
2025-11-07
Recruiting
Annexin Pharmaceuticals AB
Phase 2
12
London
2025-11-07
Recruiting
AstraZeneca
Phase 2
435
Belfast, Birmingham, Brighton, Cambridge, Dundee, Edinburgh, Exeter, Liverpool
2025-11-06
Recruiting
Sanofi
Phase 2
208
London, Leeds
2025-11-06
Recruiting
Pfizer
Phase 1
294
Sheffield
2025-11-06
Recruiting
AbbVie
Phase 3
561
Gloucester, London, Liverpool, Bristol, Newcastle upon Tyne, Sunderland
2025-11-05
Recruiting
Bristol-Myers Squibb
Phase 2/3
500
Glasgow, London, Sulton, Surrey
2025-11-05
Active, closed
Novo Nordisk A/S
Phase 3
330
Liskeard, Newquay, Torquay, Bushey, London
2025-11-05
Active, closed
Novo Nordisk A/S
Phase 3
300
Liskeard, Newquay, Torquay
2025-11-05
Recruiting
A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer
NCT07189403Advanced or Metastatic Adrenocortical Carcinoma, Metastatic Castration-resistant Prostate Cancer
Daiichi Sankyo
Phase 1
40
London
2025-11-04
Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Ribociclib·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
1,000
Brighton, London, Taunton, Guildford, Cardiff
2025-11-03
Rows per page Showing 1–500 of 2868
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site. Derived from ClinicalTrials.gov. Retrieved 15 October 2026. https://priyalifescience.com/clinical-trials-uk

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,868 studies in total at the last sync on 15 Oct 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

How many clinical trials are recruiting in the UK?

1,384 of the 2,868 studies in this register are recruiting new participants as of the 15 Oct 2026, 03:15 UTC sync. A further 59 have not yet opened recruitment, 1,338 are active but closed to new participants, and 87 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase, 2,868 studies
PhaseStudiesRecruitingShare
Phase 31,14448939.9%
Phase 248221416.8%
Observational35220412.3%
Phase 1/22731689.5%
Phase 12431288.5%
Not applicable225977.8%
Phase 2/3105593.7%
Phase 443241.5%
Early Phase 1110%

Most active sponsors

Lead sponsors with the most studies
Lead sponsorStudiesRecruiting
AstraZeneca195100
Merck Sharp & Dohme LLC11460
Hoffmann-La Roche10638
Novartis Pharmaceuticals9837
Janssen Research & Development, LLC9237
Eli Lilly and Company7445
AbbVie6827
Bristol-Myers Squibb5631
GlaxoSmithKline5634
Pfizer5626

This register, in your inbox every Friday

One email a week with how many trials are recruiting in Ireland, new EMA and FDA approvals and medicine shortages, built from the same public registers as this page.

Free. Unsubscribe from any email with one click. See our privacy policy.

→

Browse trials by condition

Breast Cancer (46) Multiple Myeloma (45) Obesity (37) Chronic Lymphocytic Leukemia (29) Ovarian Cancer (29) Heart Failure (27) Carcinoma, Non-Small-Cell Lung (27) Non-Small Cell Lung Cancer (24) Ulcerative Colitis (24) Non-small Cell Lung Cancer (23) Neoplasms (22) Crohn's Disease (22) Asthma (20) Overweight (20) Prostate Cancer (20)
→

Browse trials by city

London (2021) Manchester (667) Birmingham (482) Glasgow (437) Cambridge (424) Oxford (372) Leeds (323) Bristol (272) Liverpool (256) Newcastle upon Tyne (255) Edinburgh (255) Cardiff (242) Sutton (225) Sheffield (216) Leicester (210)
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.